Background {#Sec1}
==========

Fabry disease (FD) is a rare (frequencies of up to 1/22570 classic and 1/1390 later-onset phenotypes in males) X-linked lysosomal storage disorder caused by the deficient activity of α-galactosidase A (α-gal A) \[[@CR1]\]. This enzymatic deficit results in the cellular accumulation of globotriaosylceramide (GL-3 or Gb~3~) and related glycosphingolipids in practically all organs and tissues in the body. Males are more severely affected than females. Clinical onset of the disease typically occurs during childhood or adolescence with recurrent episodes of severe, debilitating neuropathic pain in the extremities (acroparesthesia). Patients have marked accumulation of Gb~3~ and related glycolipids in capillaries and small blood vessels, which cause the major symptoms in childhood or adolescence. These include the acroparesthesia, angiokeratomas, anhidrosis or hypohidrosis, gastrointestinal symptoms including abdominal pain and cramping, and a characteristic corneal dystrophy (cornea verticillata). With increasing age, the systemic Gb~3~ deposition leads to arrhythmias, left ventricular hypertrophy and hypertrophic cardiomyopathy in the heart. In the kidneys, it leads to microalbuminuria, proteinuria, progressive renal insufficiency and then to renal failure. In the brain, there is a risk of cerebrovascular disease including transient ischemic attacks and strokes. Specific treatment of the disease is based in enzyme replacement therapy (ERT) or migalastat therapy. While the former reduces the accumulation of the glycolipids in cells, including the cells of the kidney and other organs, the latter has been found to substantially increases alpha-galactosidase-A activity, stabilizes related serum biomarkers, and improves cardiac integrity \[[@CR2]\].

The identification of deposits of Gb~3~ at the reproductive tract level by optical and electron microscopy suggests that this part of the body might be involved \[[@CR3]--[@CR5]\]. A few case reports have been published in the literature. Very recently, an analysis of self-reported reproductive data from a large population (376 patients) of males and females with FD study carried out by Laney et al. revealed an increased reproductive fitness in this population. Nevertheless, detailed assessments on the impact of FD on the morphology and function of the reproductive system are scarce \[[@CR6]\].

Based on these data, and given the low prevalence of FD, we launched a national multicentre cross-sectional study in male FD patients. The main objective of the study was to estimate the prevalence of sperm abnormalities in patients with FD. Secondary goals included assessing the impact of these abnormalities on fertility, to study the influence of: age, severity of the disease, and treatment by enzyme replacement therapy on the presence of sperm anomalies and on fertility. An etiopathogenic diagnosis by the study of the pituitary gonadotroph function and the morphological study of the reproductive system by ultrasound scan were also carried out.

Patients and methods {#Sec2}
====================

This French study of male patients with Fabry disease was carried out in three specialized centres (Garches reference centre, Bordeaux University Hospital and the Hôpital de la Croix Saint Simon) between February 2009 and October 2013. The study was approved by the Interregional ethics committee SOOM III (N° 2008- AO1307--48). The study was registered with the European Union Drug Regulating Authorities for Clinical Trials and assigned the EudraTC No 2008-A01307--48.

Before enrolment, all patients gave informed consent. Eligibility criteria included patients aged 18 to 65 years with Fabry disease, receiving care in a specialized institution. The disease was proven by the deficient activity (\< 12%) of the enzyme alpha-galactosidase A (α-Gal A) in leukocytes. Patients under judicial protection or not affiliated to the French social security were not included in the study.

Study design {#Sec3}
------------

This was a national cross-sectional multicentre study. It included consecutively male patients with Fabry disease, regardless of whether it was the initial diagnosis or a follow-up visit, and regardless of whether they were under treatment or not. Men donated semen samples after 3 to 5 days of sexual abstinence. Semen samples were analysed in three laboratories specialized in reproductive biology that were accredited according to the ISO 15189 standard for the performance of the analyses. All three laboratories undergo the same external quality control checks twice a year on semen analyses and sperm morphology assessments. For each sample, the following characteristics were recorded: volume (mL), pH, sperm count (million/mL) and total sperm number (millions/ejaculate), sperm vitality, leucospermia, motility (initial and at 2 h) \[[@CR7]\]. The morphology of the spermatozoa was assessed by only one laboratory. Characteristics were classified according to the World Health Organization classification as normal if \[[@CR8]\]: volume more than 1.5 mL, pH greater than 7.1, sperm count more than 15 million/mL ejaculated, total sperm number more than 39 million spermatozoa per ejaculate, progressive motility value over 32%, vital spermatozoa over 58% and amount of white blood cells less than 1 million cells/mL. Sperm morphology was assessed according to the David criteria with a cut-off value of for normality of 15%, and the Multiple Anomalies Index (MAI) (\< 1.6) \[[@CR9]\].

The etiopathogenesis of possible sperm abnormalities was determined by analysing the endocrine function and by means of a genito-urinary ultrasound scan. Blood samples to evaluate the hormonal profile were collected during the inclusion visit. If laboratory standards were not specified, data were classified as missing. The genito-urinary ultrasound scan was carried out during the inclusion visit and included the following examinations: right and left testicular volumes (calculated length x width x depth × 0.71 in mm), the presence of micro calcifications (yes/no) in right and left testicles, presence of nodules (yes/no) in the right and left testicles, absence (yes/no) of right and left epididymis, absence (yes/no) of seminal vesicles, varicocele (yes/no), and prostate (normal/abnormal). The fertility of the patients was assessed during a consultation with a medical doctor specialized in reproductive health by means of a questionnaire and defined as presented in the Appendix.

Statistical analyses {#Sec4}
--------------------

Patients' demographic characteristics (age, height, weight) clinical features (heart rate and blood pressure) and medical history were described by mean (SD) or frequency (%). Sperm characteristics and infertility were described comprehensively. The primary endpoint was the prevalence of sperm abnormalities in the included patients. The prevalence of at least one abnormal category in the semen analysis was determined by the ratio between the number of patients presenting at least one abnormality and the total number of included patients. The prevalence of each abnormality was also calculated, and determined by the ratio between the number of patients with that abnormality and the total number of patients.

95% CI were estimated by the exact binomial method. Secondary endpoints were (i) the association between infertility and semen analysis abnormality; (ii) the association between potentially relevant variables and semen analysis abnormality; (iii) association between variables and infertility.

Infertility was defined as shown in the Appendix. The association between infertility and semen analysis abnormality was assessed by Fisher's exact test. Variables included in the univariable analysis were age of patient at inclusion (OR defined for an increase of one year), severity of Fabry disease (severe vs non severe), kidney failure (yes vs no), hypertrophic cardiomyopathy (yes vs no), duration of replacement therapy (increase of one month), professional or domestic exposure to products impacting on fertility (yes vs no), tobacco smoking (yes vs no), alcohol consumption (yes vs no), duration of FD from first symptoms (increase of one year), age of patient at the beginning of replacement therapy (increase of one year), active compound (α-galactosidase vs β-galactosidase). Due to the size of the sample, we adopted a strategy that included clinically relevant variables in the multivariable logistic regression model. The association of each variable with fertility or semen analysis abnormality was expressed by an OR and its bilateral 95% CI. For quantitative variables, the assumption of log-linearity of the association was systematically checked.

All analyses were carried out using a SAS version 9.3 software (SAS Institute, Cary, NC).

Results {#Sec5}
=======

Thirty-seven male patients with Fabry disease diagnosis established by a deficient activity of lysosomal α-gal A (\< 12%) and α-gal A gene mutation analysis were invited to participate in the study. Nineteen out of the 37 patients refused to participate, the reason being that the patient did not want to collect semen. In the end, 18 patients were included in the study. One patient left the study after signing the informed consent. Study duration was 59 months. The demographic and clinical characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}. All patients included in the study presented mutations causing the classical phenotype.Table 1Patients' characteristics and medical historyDemographicsn (md)Mean (SD) Age at inclusion (years)17 (1)41.5 (11.3) Height (cm)17 (1)176.7 (6.5) Weight (kg)17 (1)72.8 (13.1) Heart rate (bpm)15 (3)67.1 (14.8) Systolic blood pressure (mm Hg)15 (3)123.0 (15.9) Diastolic blood pressure (mm Hg)15 (3)77.6 (13.7)Medical historyn (md)n (%) Angiokeratomas17 (1)13 (76.5) Kidney failure17 (1)7 (41.2)  Dialysis74 (57.1)  Kidney transplantation73 (42.9) Coronary insufficiency17 (1)1 (5.9) Hypertrophic cardiomyopathy17 (1)9 (52.9) Replacement therapy17 (1)17 (100) Duration of replacement therapy (years), mean (SD)17 (1)4.8 ± 4.6 Active compound17 (1)  α-galactosidase10 (58.8)  β-galactosidase7 (41.2)*Abbreviations*: *SD* = Standard deviation; *md* = Missing data

Overall, 82.4% (95% confidence interval \[CI\], 56.6--96.2) of the patients had at least one abnormal category in the semen analysis based on WHO criteria and the David classification for morphological abnormality. A total of 58.8% (95% CI, 32.9--81.6) and 41.2% (95% CI, 18.4--67.1) of the patients presented with a decrease in the sperm number per mL and per ejaculate, respectively. Progressive motility was normal in 75% (95% CI, 47.6--92.7) of the cases. The percentage of abnormal sperm morphology according to the David classification was 53.3% (95% CI, 26.6--78.7) (Table [2](#Tab2){ref-type="table"}).Table 2Seminal characteristicsVariableTotal% (95% CI)Volume (mL)n (md)17 (1)Mean (SD)4.3 (3.1)Abnormal (\< 1.5 mL)423.5 (6.8--49.9)Normal (≥1.5 mL)1376.5 (50.1--93.2)pHn (md)17 (1)Mean (SD)7.9 (0.2)Abnormal0Normal (\> 7.2)17100 (80.5--100.0)Total sperm number (Millions/ejaculate)n (md)17 (1)Mean (SD)181.3 (265.1)Abnormal (\< 39 Millions/ejaculate)741.2 (18.4--67.1)Normal (≥39 Millions/ejaculate)1058.8 (32.9--81.6)Sperm count (Millions/mL)n (md)17 (1)Mean (SD)34.9 (53.9)Abnormal (\<  15 M/mL)1058.8 (32.9--81.6)Normal (≥ 15 M/mL)741.2 (18.4--67.1)Sperm vitality (%)n (md)17 (1)Mean (SD)58.8 (27.8)Abnormal (\<  58%)423.5 (6.8--49.9)Normal (≥ 58%)1376.5 (50.1--93.2)Presence of leucospermia (n)n (md)17 (1)Yes15.9 (0.1--28.7)No1694.1 (71.3--99.9)Progressive sperm motility (n) Grade a + bn (md)16 (2)Mean (SD)41.5 (21.2)Abnormal (\<  32%)425 (7.3--52.4)Normal (≥ 32%)1275 (47.6--92.7) Grade a + b + cn (md)16 (2)Mean (SD)48.8 (22.2)Abnormal (\<  40%)318.8 (4.0--45.6)Normal (≥ 40%)1381.3 (54.4--96.0)Sperm motility at 2 h (n) Grade a + bn (md)4 (14)Mean (SD)42.5 (32.4)Abnormal (\< 32%)125 (0.6--80.6)Normal (≥32%)375 (19.4--99.4) Grade a + b + cn (md)4 (14)Mean (SD)49.3 (33.8)Abnormal (\< 40%)125 (0.6--80.6)Normal (≥40%)375 (19.4--99.4) Sperm morphology (n)n (md)15 (3)Mean (SD)12.1 (8.7)Abnormal (\< 15%)853.3 (26.6--78.7)Normal (≥15%)746.7 (21.3--73.4) MAI (n)n (md)15 (3)Mean (SD)1.7 (0.3)Abnormal (≥1.6)1066.7 (38.4--88.2)Normal (\< 1.6)533.3 (11.8--61.6)*Abbreviations:* md = missing data; CI = confidence interval; SD = standard deviation; MAI = Multiple Anomalies Index

Eleven (68.8%) out of 16 patients (hormonal data was missing for one patient) had a normal hormonal profile, four (36.4%) of which had sperm abnormalities (Table [3](#Tab3){ref-type="table"}). The number of semen analysis abnormality cases increased twice (4 out of 5 patients, 80%) among patients with an abnormal hormonal profile (5 out of 16 patients, 31.3%). Overall, ultrasound scans revealed abnormalities in the genital tract morphology in 76.5% of the patients. The mean (standard deviation \[SD\]) volumes of the right and left testes were 10.2 mL (3.0) and 9.5 mL (3.1), respectively. Micro-calcifications were identified throughout both testicles in 41.2% (7 out of 17) of the patients. Testicular lumps were detected in 17.6% (right testicle) and 5.9% (left testicle) of the patients. There were 41.2 and 58.8% of patients with right and left epididymal cysts, respectively. Abnormal seminal vesicles were detected in 20% of patients, all of whom presented semen abnormalities. Varicocele affected 5 patients (1 right varicocele, 3 left varicocele and 1 right and left varicocele) and four of them presented sperm abnormalities. Prostate was normal in 64.7% of the patients.Table 3Hormonal profileVariableTotalNormal semen analysisAbnormal category in the semen analysisTotal testosterone (n, %)n (md)10 (7)4 (4)6 (3)normal1046Sex Hormone-binding globulin S-HBG) (nmol/L)n (md)9 (8)2 (6)7 (2)Normal514Abnormal413Follicle stimulating hormone (FSH) (mU/mL)n (md)13 (4)6 (2)7 (2)Normal624Abnormal743Luteinizing hormone (LH) (mU/mL)n (md)13 (4)6 (2)7 (2)Normal1266Abnormal101Inhibin B (pg/mL)n (md)10 (7)5 (3)5 (4)Normal853Abnormal20217β estradiol (pmol/L)n (md)14 (3)6 (2)8 (1)Normal624Abnormal844Prolactine (PRL) (pmol/L)n (md)9 (8)6 (2)3 (6)Normal642Abnormal321Overall resultn (md)16 (1)88 (1)Normal1174Abnormal514*Abbreviations*: *md* = missing data

Sixteen patients responded to the questionnaire on fertility, of whom 11 (68.8%) were classified as fertile. Nine (81.8%) out of the 11 fertile patients presented at least one abnormal category in the semen analysis.

The five patients that had scored as "undetermined" in the fertility questionnaire were considered as infertile for the statistical model. Fisher's exact test revealed no association between infertility and semen analysis abnormality (*p* = 1.0000).

Age of the patient at inclusion, age of patient at the beginning of therapy, duration of replacement therapy and alcohol consumption were associated to the presence of sperm abnormalities in univariable analysis. Variables included in the multivariable analysis due to its clinical relevance were age of patient at inclusion, duration of replacement treatment and active compound. Older patients at inclusion (odds ratio \[OR\], 1.19; 95% CI, 0.98 to 1.45. *p* = 0.0854) and patients with a longer duration of replacement therapy (OR, 1.28; 95% CI, 0.96 to 1.65; *p* = 0.1263) were more likely to present abnormalities in the semen analysis (Table [4](#Tab4){ref-type="table"}).Table 4Association of variables with abnormalities in semen analysisVariablenUnivariable analysisFinal multivariable model (*n* = 17)OR95% CI*p*-valueOR95% CI*p*-valueAge of patient at inclusion17For the increase of one year1.161.01--1.33***0.0403***1.190.98--1.450.0854Severity of FD171 - Severe vs **0 - Non severe**1.170.12--10.990.8927Kidney failure171 - Yes vs **0 - No**1.330.19--9.310.7717Hypertrophic cardiomyopathy171 - Yes vs **0 - No**0.480.07--3.350.4592Duration of replacement treatment17For the increase of 1 year1.260.96--1.65*0.0965*1.280.93--1.740.1263Professional or domestic exposure171 - Yes vs **0 - No**0.870.05--16.740.9292Tobacco consumption171 - Yes vs **0 - No**0.480.06--3.990.4939Alcohol consumption171 - Yes vs **0 - No**0.300.04--2.2*0.2363*Duration of FD from first symptoms16For the increase of 1 year1.050.96--1.160.2866Age of patient at the beginning of replacement therapy17For the increase of 1 year1.090.98--1.22*0.1222*Active compound171 - α-galactosidase vs **2 - ß-galactosidase**2.000.28--14.20.48823.770.21--66.80.3662*Abbreviations: CI* = confidence interval; *OR* = odds ratio; *FD* = Fabry diseaseThe references for OR are in bold

Alcohol consumption (*p* = 0.2399) and a more severe FD (*p* = 0.1959) were found to increase the risk of infertility in the univariable model, although not in a statistically significant way (Table [5](#Tab5){ref-type="table"}). Since no patient had the infertile status, no further multivariable analysis was carried out.Table 5Association of variables with fertilityVariablenUnivariable analysisOR95% CI (OR)p-valueAge of patient at inclusion16For the increase of one year1.010.92--1.110.7839Severity of FD161 - Severe vs **0 - Non-severe**0.150.01--2.29*0.1724*Duration of replacement treatment15For the increase of 1 year1.000.98--1.020.8776Professional or domestic exposure161 - Yes vs **0 - No**2.500.12--50.440.5501Tobacco consumption161 - Yes vs **0 - No**0.440.04--5.400.5189Alcohol consumption161 - Yes vs **0 - No**0.210.02--2.52*0.2173Abbreviations*: *OR* = Odds ratio; *CI* = confidence interval; *FD* = Fabry diseaseThe references for OR are in bold

Discussion {#Sec6}
==========

We and others have reported individual cases of Gb~3~ (or GL-3) storage in the reproductive system of patients with FD, with inconsistent results regarding fertility. However, the association between the storage of Gb~3~ or the impact of FD on reproductive function has not been established in large FD populations \[[@CR3]--[@CR5], [@CR10]--[@CR12]\].

Patients included in this study presented classical symptoms including hypertrophic cardiomyopathy (52.9%), kidney failure (41.2%) and coronary insufficiency (5.9%). The incidence of dermatological and ophthalmological manifestations was slightly lower than that described in the literature. Overall, 76.5 and 47.1% of patients presented with angiokeratomas and cornea verticillata, respectively \[[@CR13]\].

The progressive accumulation of Gb~3~ in the testes and epididymis has been associated with semen abnormalities \[[@CR3], [@CR4]\]. In our study, 82.4% of patients showed abnormalities in the semen analysis based on WHO criteria. Considering the parameters that are clinically significant for reproductive health, it was concluded that 52.9% of patients had at least one abnormality in semen. Most common alterations included a reduced sperm count (58.8% of patients), followed by semen volume and sperm vitality (23.5% for both). Progressive and total motility were altered for 25 and 18.8% of the patients, respectively. These results together with previous results suggest that FD might have a detrimental effect in the gonadal function \[[@CR14]\]. Multivariable analysis revealed that severe (vs non-severe) disease was not associated with semen abnormalities. Only age of the patient at inclusion (*p* = 0.0854) and duration of ERT treatment (*p* = 0.1263) were associated in univariable analysis, but did not reach statistical significance. We investigated the nature of treatment impact by including the type of treatment as a variable in the multivariable analysis. There was no significant difference between patients treated with α-galactosidase and those treated with β-galactosidase. To our knowledge, this is the first study prospectively evaluating semen characteristics in Fabry patients.

Relating FD to male reproductive function is complex since the ability of a couple to conceive depends on both male and female factors. Fertility incidence in this study (68.8%) was consistent with the recent report of Laney et al. in which 64% of males with FD reported not having issues with infertility, but lower than the reported general population rate of 88--97.5% \[[@CR15]\]. These results are in line with our analyses that reveal that severity of FD is not significantly associated with fertility (*p* = 0.1724) in univariable analysis. However, this result should be interpreted with caution due to small sample.

Also, four patients in this study received dialysis and three of them underwent a transplantation. Two of them were able to conceive without difficulty at least 6 years before the dialysis, and had two and three children respectively. Only one of them presented a sperm motility alteration, 7 years after the onset of renal failure. The other two patients were single. For one of them, an azoospermia was diagnosed at the age of 49, 15 years after the renal failure onset and after a cardiac transplantation. The second one had an oligozoospermia diagnosed 3 years after the onset of renal failure at the age of 52. The impact of renal failure on these alterations cannot therefore be ruled out and must be taken into consideration in patients with FD \[[@CR16]\].

According to data published in the literature, Gb~3~ depositions in the endocrine system do not play a major clinical role in this disease in terms of hormone levels \[[@CR17]\]. Our results were consistent with these findings in that the hormonal function of most patients was normal. Hauser et al. studied the impact of FD on endocrine organs and on the fertility fitness. The profile of gonadotropins and sex hormones as well as fertility rates in patients with FD were comparable to those of the Austrian general population \[[@CR17]\]. Similarly, Faggiano et al. compared the function and morphology of endocrine glands among 18 patients with Fabry disease and age-matched healthy controls. Even though several endocrine dysfunctions were detected in FD patients, neither basal and stimulated FSH and LH levels nor sexual hormone levels differed significantly from controls \[[@CR18]\].

Concerning morphology of the genital tract, over 76% of patients presented anomalies. Most common anomalies were micro-calcifications in both testes and epididymal cysts, the latter often resulting in obstructive azoospermia \[[@CR19]\].

Potential limitations of our study include the low statistical power due to the poor patient recruitment rate. Some variables were included in the final multivariable model due to their clinical rather than statistical significance. Inclusion was challenging, and led to reducing the initially planned two semen analyses to a single one. In addition, the study reports on data from three centres, resulting in a lack of representativeness. On the other hand, while recent reports have been published on larger cohorts, the present study is of prospective nature. In addition, it provides a detailed assessment of morphology and function and a description of variables related to fertility.

Conclusions {#Sec7}
===========

In conclusion, these results suggest that, while FD might have a detrimental effect on the semen characteristics of patients, the reproductive function remains only slightly diminished. Further studies are warranted to assess the extent of the disease in the fertility of male patients with FD.

Appendix {#Sec8}
========

Table 6Fertility questionnaireInfertility of current coupleInfertility of previous coupleInfertility of current partnerInfertilityYesYesNoYesYesNoNoUndeterminedYesNoYesUndeterminedYesYesYesUndeterminedNoYes or noNon-exploredNo

CI

:   confidence interval

ERT

:   enzyme replacement therapy

FD

:   Fabry disease

GL-3 or Gb~3~

:   globotriaosylceramide

MAI

:   Multiple Anomalies Index

MD

:   missing data

OR

:   odds ratio

SD

:   standard deviation

α-gal A

:   α-galactosidase A
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